Log In
Print
BCIQ
Print
Print this Print this
 

NEOD001

  Manage Alerts
Collapse Summary General Information
Company Prothena Corp. plc
DescriptionHumanized mAb targeting amyloid
Molecular Target Amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationAmyloidosis
Indication DetailsTreat amyloid A (AA) amyloidosis; Treat amyloid light-chain (AL) amyloidosis
Regulatory Designation U.S. - Fast Track (Treat amyloid A (AA) amyloidosis)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today